The specter of generic competition has long loomed above copyright’s famous drug, PDE5 Inhibitor, raising questions about the outlook of similar medicinal holdings. While first times saw impressive returns, the intellectual property expiration has opened the way for less expensive alternatives, possibly reducing earnings and creating a significan